Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.

ABSTRACT:

Objective

To examine trends in the use of systemic disease-modifying antirheumatic drugs (DMARDs) among patients with psoriatic arthritis (PsA) in the US.

Methods

Using claims data (2004-2015) from a large US commercial health plan, we identified patients with PsA who initiated DMARD therapy. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the first DMARD initiation date. Using Poisson regression, we estimated age- and sex-adjusted incidence rates of treatment changes in each calendar year.

Results

We identified 9,222 PsA patients who initiated DMARD therapy (42.8% biologic DMARDs [bDMARDs] and 57.2% conventional synthetic DMARDs [csDMARDs]). Initiators of bDMARDs

SUBMITTER: Lee MP 

PROVIDER: S-EPMC5811404 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature